| Abstrakt: |
Appistry, Inc., a leading provider of tools, software, and services that bring the power of genomics to next-generation medicine, today announced an agreement with Personal Genome Diagnostics (PGDx) to include the company’s CancerSelect™ panel in Appistry’s recently released Appistry CloudDx™ genomics testing service. PGDx, a provider of CLIA-compliant genomics services to oncology researchers, drug developers, clinicians, and patients, is among the first organizations to offer lab-developed tests (LDTs) through Appistry’s cloud-based service that makes LDTs from leading diagnostic test providers available to physicians across the United States. Appistry CloudDx was launched at the 2014 ASCO Annual Meeting held in Chicago May 30–June 3, 2014. [ABSTRACT FROM PUBLISHER] |
